Boehringer Ingelheim is teaming up with the Mumbai, India–based drug company Lupin to bolster its KRas inhibitor program for gastrointestinal and lung cancers. Lupin has developed an inhibitor of MEK, a protein downstream of KRas. Boehringer will pay Lupin $20 million up front to license and test Lupin’s MEK inhibitor in combination with a KRas inhibitor. Lupin could also receive more than $700 million in future milestone payments. Separately, Boehringer recently announced a drug development partnership with the University of Texas MD Anderson Cancer Center to test its KRas inhibitors.